Core Insights - Hemostemix Inc. has launched VesCell.Health in Florida, an educational website aimed at helping physicians and patients understand the benefits of its autologous stem cell therapy, VesCell™ [1][4] - Florida's law SB 1768 now allows the use of VesCell™ for patients with life-threatening or debilitating conditions who have exhausted standard treatment options [2] Company Overview - Hemostemix is a leading autologous stem cell therapy company founded in 2003, recognized as a World Economic Forum Technology Pioneer [5] - The company has developed and patented VesCell™ (ACP-01), which has shown safety and efficacy in treating various conditions, including peripheral arterial disease and chronic limb threatening ischemia [5] Clinical Evidence - VesCell.Health provides accessible explanations of VesCell™ and presents evidence-based results from 11 peer-reviewed publications across seven clinical trials, including a Phase II trial for Critical Limb Threatening Ischemia (CLTI) [3][7] - The Phase II trial reported a 0% mortality rate and wound healing in 83% of patients over a follow-up period of up to 4.5 years, compared to a 50% five-year mortality rate in the general CLTI patient population [5] Educational Initiative - The website aims to present complex clinical research in layman's terms, making the benefits of VesCell™ clear and approachable for both physicians and patients [4][3] - It serves as a trusted repository for clinical evidence, ensuring that information is aligned with regional regulatory frameworks and treatment pathways for Florida residents [7]